Anti Inflammatory News and Research

RSS

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Electromagnetic pulses significantly decrease pain and inflammation associated with osteoarthritis of the knee, according to Henry Ford Hospital researchers.

7 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically increased in health care institutions for inappropriate indications, route of administration and length of treatment. This is associated with an increased cost burden, increased risk of IV related infections, and utilization of hospital resources.

6 Mar 2010

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called CYTOMIMIC™ Technology, is a proprietary, patented technology that combines essential minerals to deliver biological levels of electric signals similar to the skin's natural bioelectricity.

5 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

People with skin of color more prone to dermatologic problems than those with lighter skin tones

According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.

5 Mar 2010

Common allergens that may cause contact dermatitis

Itchy irritated skin can leave some people scratching their heads trying to determine the cause of this bothersome condition. What did they touch? Is it just dry skin gone awry? Are they allergic to something in their home or workplace? The answers to these questions could require not only a little detective work, but the help of a dermatologist who can diagnose and treat the most likely culprit - contact dermatitis.

5 Mar 2010

Gene involved in susceptibility and resistance to TB identified

University of Washington researchers have identified a gene involved in susceptibility and resistance to tuberculosis. This same gene, they have found, has a role in the severity of leprosy, which is caused by a related pathogen. The researchers also have learned why this gene is important for susceptibility.

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Soluble fiber in oats, apples and nuts reduces inflammation; strengthens immune system

A new University of Illinois study touts the benefits of soluble fiber-found in oats, apples, and nuts, for starters-saying that it reduces the inflammation associated with obesity-related diseases and strengthens the immune system.

3 Mar 2010

InterMune seeks European marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the European Union (EU). Currently, there are no EMA-approved treatments for IPF in the EU.

2 Mar 2010

Habits of modern life may shorten life-span of the Millennium Generation

All parents dream of a better life for their children, but because of the habits of modern life, the Millennium Generation may be the first to suffer a shorter life-span.

1 Mar 2010

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.

1 Mar 2010

Republicans press campaign against reconciliation; Mccain seek to strip Medicare out of health bill

Republicans and Democrat hit the Sunday talk shows today to debate whether a complex congressional process called 'reconciliation' should be used to consider a major overhaul of the U.S. health care system. Reconciliation is normally used for 'taxing and spending and reducing deficits,' said Sen.

28 Feb 2010

Heel pain continues to be the most common reason patients seek care, say foot and ankle surgeons

If you are suffering from heel pain, you're not alone. According to foot and ankle surgeons attending the 68th Annual Scientific Conference of the American College of Foot and Ankle Surgeons in Las Vegas this week, heel pain continues to be the most common reason patients seek care. Surgeons advise the best defense to keeping pain in control is early treatment.

26 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

AOSSM and RTI Biologics award $250,000 grant for ligament and tendon repair and regeneration research

Dr. Robert C. Bray of the University of Calgary was recently selected as the winner of the American Orthopaedic Society for Sports Medicine's (AOSSM) $250,000 Ligament and Tendon Repair and Regeneration Grant for his project, "Biological Augmentation of Ligament and Tendon Healing: Role of Neuropeptides."

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

Anti Inflammatory News and Research

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

People with skin of color more prone to dermatologic problems than those with lighter skin tones

Common allergens that may cause contact dermatitis

Gene involved in susceptibility and resistance to TB identified

Proper diagnosis, treatment and good skin care help control acne and rosacea

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Soluble fiber in oats, apples and nuts reduces inflammation; strengthens immune system

InterMune seeks European marketing approval for pirfenidone

Habits of modern life may shorten life-span of the Millennium Generation

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

Republicans press campaign against reconciliation; Mccain seek to strip Medicare out of health bill

Heel pain continues to be the most common reason patients seek care, say foot and ankle surgeons

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

AOSSM and RTI Biologics award $250,000 grant for ligament and tendon repair and regeneration research

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News